AbbVie’s Skyrizi Tops Novartis’s Cosentyx In Psoriasis Contest

Head-To-Head Result Will Fuel IL-23 Versus IL-17 Debate

 
• By Sten Stovall
Chess_Pieces
Skyrizi beat Cosentyx in their Phase III trial

More from Clinical Trials

More from R&D